Breaking News

Saturday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
International Assoc for the Study of Lung Cancer to hold a virtual conference » 04:55
10/17/20
10/17
04:55
10/17/20
04:55
GTHX

G1 Therapeutics

$13.57 /

+0.28 (+2.11%)

2020 North America…

2020 North America Virtual Conference on Lung Cancer will be held on October 16-17.Webcast Link

ShowHide Related Items >><<
GTHX G1 Therapeutics
$13.57 /

+0.28 (+2.11%)

GTHX G1 Therapeutics
$13.57 /

+0.28 (+2.11%)

07/01/20 Wedbush
G1 Therapeutics price target lowered to $50 from $55 at Wedbush
06/26/20 Roth Capital
G1 Therapeutics initiated with a Buy at Roth Capital
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
GTHX G1 Therapeutics
$13.57 /

+0.28 (+2.11%)

Friday
Conference/Events
International Assoc for the Study of Lung Cancer to hold a virtual conference » 08:48
10/16/20
10/16
08:48
10/16/20
08:48
GTHX

G1 Therapeutics

$13.27 /

-0.18 (-1.34%)

2020 North America…

2020 North America Virtual Conference on Lung Cancer will be held on October 16-17.Webcast Link

ShowHide Related Items >><<
GTHX G1 Therapeutics
$13.27 /

-0.18 (-1.34%)

GTHX G1 Therapeutics
$13.27 /

-0.18 (-1.34%)

07/01/20 Wedbush
G1 Therapeutics price target lowered to $50 from $55 at Wedbush
06/26/20 Roth Capital
G1 Therapeutics initiated with a Buy at Roth Capital
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
GTHX G1 Therapeutics
$13.27 /

-0.18 (-1.34%)

Over a week ago
Hot Stocks
G1 Therapeutics CEO Mark Velleca to move to new role, John Bailey to succeed » 16:05
09/30/20
09/30
16:05
09/30/20
16:05
GTHX

G1 Therapeutics

$11.59 /

-0.32 (-2.69%)

, GSK

GlaxoSmithKline

$37.65 /

+0.22 (+0.59%)

G1 Therapeutics (GTHX)…

G1 Therapeutics (GTHX) announced that effective January 1, 2021, Mark Velleca will transition to the role of senior advisor and continue to serve as a member of the G1 board. John Bailey, a member of the company's board, has been named as G1's next CEO. Bailey has nearly thirty years of commercial pharmaceutical experience. He has experience guiding the launch and growth of multiple pharmaceutical products. Most recently, Bailey served as president of GlaxoSmithKline's (GSK) pharmaceuticals and vaccines business in the U.S., with responsibility for commercialization efforts across the company's oncology, immunology/rare disease, respiratory and vaccines portfolios.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$11.59 /

-0.32 (-2.69%)

GSK GlaxoSmithKline
$37.65 /

+0.22 (+0.59%)

GTHX G1 Therapeutics
$11.59 /

-0.32 (-2.69%)

07/01/20 Wedbush
G1 Therapeutics price target lowered to $50 from $55 at Wedbush
06/26/20 Roth Capital
G1 Therapeutics initiated with a Buy at Roth Capital
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
GSK GlaxoSmithKline
$37.65 /

+0.22 (+0.59%)

09/29/20 Berenberg
GlaxoSmithKline initiated with a Buy at Berenberg
09/23/20 Oddo BHF
GlaxoSmithKline upgraded to Buy from Neutral at Oddo BHF
09/18/20 Societe Generale
GlaxoSmithKline price target raised to 2,350 GBp at Societe Generale
09/08/20 JPMorgan
GlaxoSmithKline price target lowered to 1,650 GBp from 1,700 GBp at JPMorgan
GTHX G1 Therapeutics
$11.59 /

-0.32 (-2.69%)

GSK GlaxoSmithKline
$37.65 /

+0.22 (+0.59%)

GSK GlaxoSmithKline
$37.65 /

+0.22 (+0.59%)

GSK GlaxoSmithKline
$37.65 /

+0.22 (+0.59%)

GSK GlaxoSmithKline
$37.65 /

+0.22 (+0.59%)

Conference/Events
G1 Therapeutics management to meet virtually with BTIG » 04:55
09/23/20
09/23
04:55
09/23/20
04:55
GTHX

G1 Therapeutics

$13.59 /

-0.66 (-4.63%)

Virtual Meeting to be…

Virtual Meeting to be held on September 23 hosted by BTIG.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$13.59 /

-0.66 (-4.63%)

GTHX G1 Therapeutics
$13.59 /

-0.66 (-4.63%)

07/01/20 Wedbush
G1 Therapeutics price target lowered to $50 from $55 at Wedbush
06/26/20 Roth Capital
G1 Therapeutics initiated with a Buy at Roth Capital
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
GTHX G1 Therapeutics
$13.59 /

-0.66 (-4.63%)

Over a month ago
Conference/Events
G1 Therapeutics management to meet virtually with BTIG » 12:38
09/17/20
09/17
12:38
09/17/20
12:38
GTHX

G1 Therapeutics

$15.58 /

-0.38 (-2.38%)

Virtual Meeting to be…

Virtual Meeting to be held on September 23 hosted by BTIG.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$15.58 /

-0.38 (-2.38%)

GTHX G1 Therapeutics
$15.58 /

-0.38 (-2.38%)

07/01/20 Wedbush
G1 Therapeutics price target lowered to $50 from $55 at Wedbush
06/26/20 Roth Capital
G1 Therapeutics initiated with a Buy at Roth Capital
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
GTHX G1 Therapeutics
$15.58 /

-0.38 (-2.38%)

Hot Stocks
G1 Therapeutics announces FDA acceptance of trilaciclib NDA » 06:02
08/17/20
08/17
06:02
08/17/20
06:02
GTHX

G1 Therapeutics

$15.85 /

-0.46 (-2.82%)

G1 Therapeutics announced…

G1 Therapeutics announced that the FDA has accepted the new drug application, or NDA, for trilaciclib for small cell lung cancer, or SCLC, patients being treated with chemotherapy and granted priority review with a Prescription Drug User Fee Act action date of February 15, 2021. Trilaciclib is an investigational therapy designed to preserve bone marrow and immune system function during chemotherapy and improve patient outcomes.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$15.85 /

-0.46 (-2.82%)

GTHX G1 Therapeutics
$15.85 /

-0.46 (-2.82%)

07/01/20 Wedbush
G1 Therapeutics price target lowered to $50 from $55 at Wedbush
06/26/20 Roth Capital
G1 Therapeutics initiated with a Buy at Roth Capital
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
GTHX G1 Therapeutics
$15.85 /

-0.46 (-2.82%)

Earnings
G1 Therapeutics reports Q2 EPS (83c), consensus (83c) » 16:14
08/05/20
08/05
16:14
08/05/20
16:14
GTHX

G1 Therapeutics

$15.54 /

+0.14 (+0.91%)

Reports Q2 revenue…

Reports Q2 revenue $2.14less thanM, consensus $2.25M. We made substantial progress on a number of fronts in the first half of 2020, and sharpened our focus on bringing trilaciclib to patients in 2021. By forging four strategic collaborations and securing a flexible credit facility, we have achieved three important objectives: positioning G1 for a strong commercial launch of trilaciclib in the United States, providing global access to our therapies, and securing non-dilutive capital to support the continued development of trilaciclib in additional indications," said Mark Velleca, M.D., Ph.D., Chief Executive Officer. "We are now executing a comprehensive launch strategy for trilaciclib designed to raise awareness of the burden that chemotherapy-induced myelosuppression places on patients and the healthcare system, as well as implementing a robust development plan to evaluate the benefits of trilaciclib in additional tumor types and chemotherapy regimens."

ShowHide Related Items >><<
GTHX G1 Therapeutics
$15.54 /

+0.14 (+0.91%)

GTHX G1 Therapeutics
$15.54 /

+0.14 (+0.91%)

07/01/20 Wedbush
G1 Therapeutics price target lowered to $50 from $55 at Wedbush
06/26/20 Roth Capital
G1 Therapeutics initiated with a Buy at Roth Capital
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
GTHX G1 Therapeutics
$15.54 /

+0.14 (+0.91%)

Hot Stocks
G1 Therapeutics, Simcere enter license agreement for trilaciclib » 07:20
08/03/20
08/03
07:20
08/03/20
07:20
GTHX

G1 Therapeutics

$14.64 /

-1.15 (-7.28%)

G1 Therapeutic announced…

G1 Therapeutic announced an exclusive license agreement for the development and commercialization of trilaciclib across all indications in Greater China. Discovered and developed by G1, trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy. Under the terms of the agreement, G1 will receive an upfront payment of $14M and be eligible to receive up to $156M in development and commercial milestone payments. Simcere will also pay G1 tiered low double-digit royalties on annual net sales of trilaciclib in Greater China. Simcere will have exclusive development and commercialization rights for trilaciclib for all indications in Greater China, and will participate in global clinical trials of trilaciclib. G1 retains development and commercialization rights to trilaciclib in all territories outside of Greater China. The companies will be responsible for all development and commercialization costs in their respective territories.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$14.64 /

-1.15 (-7.28%)

GTHX G1 Therapeutics
$14.64 /

-1.15 (-7.28%)

07/01/20 Wedbush
G1 Therapeutics price target lowered to $50 from $55 at Wedbush
06/26/20 Roth Capital
G1 Therapeutics initiated with a Buy at Roth Capital
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
GTHX G1 Therapeutics
$14.64 /

-1.15 (-7.28%)

Over a quarter ago
Hot Stocks
G1 Therapeutics signs license agreement for lerociclib including $20M payment » 18:03
07/22/20
07/22
18:03
07/22/20
18:03
GTHX

G1 Therapeutics

$18.15 /

-0.12 (-0.66%)

G1 Therapeutics announced…

G1 Therapeutics announced a license agreement for lerociclib to EQRx, a biopharmaceutical company. EQRx gains exclusive rights for lerociclib in the U.S., Europe, Japan and all other global markets, excluding the Asia-Pacific region except Japan. G1 will receive an upfront cash payment of $20M and will be eligible to receive development and commercial milestone payments of up to $290M, plus tiered royalties ranging from mid-single digits to mid-teens based on annual net sales of lerociclib. Discovered and developed by G1, lerociclib has demonstrated clinical proof-of-concept and a differentiated profile in a Phase 1/2 trial in patients with ER+, HER2- breast cancer. Earlier this year, G1 licensed development and commercialization rights in the Asia-Pacific region excluding Japan to Genor Biopharma. Lerociclib is a differentiated oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in certain types of breast and lung cancer

ShowHide Related Items >><<
GTHX G1 Therapeutics
$18.15 /

-0.12 (-0.66%)

GTHX G1 Therapeutics
$18.15 /

-0.12 (-0.66%)

07/01/20 Wedbush
G1 Therapeutics price target lowered to $50 from $55 at Wedbush
06/26/20 Roth Capital
G1 Therapeutics initiated with a Buy at Roth Capital
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
GTHX G1 Therapeutics
$18.15 /

-0.12 (-0.66%)

Conference/Events
G1 Therapeutics to hold a webinar with Roth Capital » 11:25
07/08/20
07/08
11:25
07/08/20
11:25
GTHX

G1 Therapeutics

$20.88 /

-0.28 (-1.32%)

Head of Biotech Research,…

Head of Biotech Research, Tony Butler, holds a webinar to discuss cytotoxic chemotherapy on July 8 at 12 pm hosted by Roth Capital.

ShowHide Related Items >><<
GTHX G1 Therapeutics
$20.88 /

-0.28 (-1.32%)

GTHX G1 Therapeutics
$20.88 /

-0.28 (-1.32%)

07/01/20 Wedbush
G1 Therapeutics price target lowered to $50 from $55 at Wedbush
06/26/20 Roth Capital
G1 Therapeutics initiated with a Buy at Roth Capital
05/27/20 JonesTrading
JonesTrading sees potential positive myelopreservation data in June for Aileron
02/27/20 Wedbush
G1 Therapeutics price target lowered to $55 from $67 at Wedbush
GTHX G1 Therapeutics
$20.88 /

-0.28 (-1.32%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.